Golden Robert N
Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599-7160, USA.
Psychopharmacol Bull. 2003 Spring;37 Suppl 1:176-86.
Paroxetine controlled-release (CR) was developed with the objective of minimizing the occurrence and severity of selective serotonin reuptake inhibitor (SSRI)-associated adverse events, thereby improving clinical outcomes. Paroxetine CR delays the onset and controls the rate of absorption of medication. Multicenter controlled clinical trials have found lower rates of early-onset, treatment-associated nausea and lower dropout rates from adverse events in depressed patients treated with paroxetine CR compared with those treated with the conventional, immediate-release formulation. At the same time, clinical response and remission rates are favorable. Other studies have demonstrated the efficacy and tolerability of paroxetine CR in geriatric depression, panic disorder, and social anxiety disorder. The CR formulation of paroxetine appears to represent an effective pharmacokinetic approach to minimizing SSRI adverse events and thereby enhancing clinical outcomes.
帕罗西汀控释片（CR）的研发目的是尽量减少选择性5-羟色胺再摄取抑制剂（SSRI）相关不良事件的发生及严重程度，从而改善临床疗效。帕罗西汀CR可延迟起效并控制药物吸收速率。多中心对照临床试验发现，与使用传统速释制剂的抑郁症患者相比，使用帕罗西汀CR治疗的患者早期出现与治疗相关恶心的发生率较低，因不良事件导致的停药率也较低。同时，临床反应和缓解率良好。其他研究已证明帕罗西汀CR在老年抑郁症、惊恐障碍和社交焦虑症中的疗效及耐受性。帕罗西汀的控释制剂似乎是一种有效的药代动力学方法，可将SSRI不良事件降至最低，从而提高临床疗效。
